These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 16896075)

  • 1. FDA's monitoring of postmarketing studies probed.
    Young D
    Am J Health Syst Pharm; 2006 Aug; 63(16):1485-6. PubMed ID: 16896075
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 3. Monitoring drug product quality.
    Bolger G; Goetsch R; Reinstein P
    Am Pharm; 1992 Feb; NS32(2):47-9. PubMed ID: 1546630
    [No Abstract]   [Full Text] [Related]  

  • 4. After Avandia, some seek split in drug approval and monitoring.
    Dolgin E
    Nat Med; 2010 Aug; 16(8):831. PubMed ID: 20689527
    [No Abstract]   [Full Text] [Related]  

  • 5. Regulatory experts debate FDA's authority.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA post-marketing safety decisions.
    Klein DF
    J Clin Psychiatry; 2006 Aug; 67(8):1305-6. PubMed ID: 16965212
    [No Abstract]   [Full Text] [Related]  

  • 7. A primer of drug safety surveillance: an industry perspective. Part I: Information flow, new drug development, and federal regulations.
    Allan MC
    J Pharm Technol; 1992; 8(4):162-7. PubMed ID: 10121011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.
    Ball R; Robb M; Anderson SA; Dal Pan G
    Clin Pharmacol Ther; 2016 Mar; 99(3):265-8. PubMed ID: 26667601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to avoid another 'Vioxx'.
    Frantz S
    Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

  • 12. Reviving the FDA's Authority to Publicly Explain Why New Drug Applications Are Approved or Rejected.
    Herder M
    JAMA Intern Med; 2018 Aug; 178(8):1013-1014. PubMed ID: 29971404
    [No Abstract]   [Full Text] [Related]  

  • 13. [Drug safety: from development to clinical use].
    Ovchinnikova EA; Gerasimov VB
    Antibiot Khimioter; 2006; 51(6):15-22. PubMed ID: 17523417
    [No Abstract]   [Full Text] [Related]  

  • 14. MedWatch. FDA's 'heads up' on medical product safety.
    Henkel J
    FDA Consum; 1998; 32(6):10-2, 15. PubMed ID: 9854445
    [No Abstract]   [Full Text] [Related]  

  • 15. MedWatch: FDA's Medical Products Reporting Program.
    Goldman SA; Kennedy DL
    Postgrad Med; 1998 Mar; 103(3):13-6. PubMed ID: 9519028
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA's MedWatch Program Monitors Drug Safety, But It Depends on Nurses to Report Adverse Events.
    Miller D
    ONS Connect; 2015 Sep; 30(3):49. PubMed ID: 26449124
    [No Abstract]   [Full Text] [Related]  

  • 17. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 18. Monitoring adverse drug events: the Food and Drug Administration MedWatch reporting system.
    Landow L
    Reg Anesth Pain Med; 1998; 23(6 Suppl 2):190-3. PubMed ID: 9845393
    [No Abstract]   [Full Text] [Related]  

  • 19. The FDA's poor oversight of postmarketing studies.
    Lancet; 2009 Nov; 374(9701):1568. PubMed ID: 19897111
    [No Abstract]   [Full Text] [Related]  

  • 20. Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database.
    Florek AG; Nardone B; Thareja S; Tran G; Giles FJ; West DP
    Br J Dermatol; 2017 Nov; 177(5):e220-e221. PubMed ID: 28646575
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.